Arbutus Biopharma Corporation ABUS Investment Proceeds
Investment Proceeds at other companies
Other financials
Where this comes from
Reported directly by Arbutus Biopharma Corporation in its filing.
Tagged under the XBRL concept us-gaap:ProceedsFromSaleMaturityAndCollectionsOfInvestments.
The official record: Arbutus Biopharma Corporation’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →
Ask your AI about Arbutus Biopharma Corporation's investment proceeds.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Arbutus Biopharma Corporation's investment proceeds?
- Arbutus Biopharma Corporation (ABUS) reported investment proceeds of $16M in Q1 2026.
- How has Arbutus Biopharma Corporation's investment proceeds changed year-over-year?
- Arbutus Biopharma Corporation's investment proceeds decreased by 65.3% year-over-year, from $46.07M to $16M.
- What is the long-term trend for Arbutus Biopharma Corporation's investment proceeds?
- Over 4 years (2021 to 2025), Arbutus Biopharma Corporation's investment proceeds has grown at a 21.9% compound annual growth rate (CAGR), from $70.35M to $155.28M.
- What does investment proceeds mean?
- Cash received from sales, maturities, and redemptions of investment securities across all categories.